Key Points
- Insider sale: Robert Allen III sold 17,043 Invivyd shares for $14,316 at an average price of $0.84, reducing his stake by 8.7%. The sale covered tax-withholding obligations from vested equity awards.
- Weak quarterly results: Invivyd reported a quarterly loss of $0.14 per share, missing estimates by $0.03, while revenue of $14.29 million came in slightly below forecasts.
- Mixed outlook: Institutional investors own 70.36% of the company, while analysts’ ratings range from Buy to Sell. The consensus rating is Hold, with an average price target of $8.00, compared with the stock’s recent price below $1.
Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) insider Robert Allen III sold 17,043 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $0.84, for a total value of $14,316.12. Following the transaction, the insider owned 178,765 shares of the company's stock, valued at approximately $150,162.60. This trade represents a 8.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Invivyd Price Performance
IVVD opened at $0.87 on Wednesday. The company has a market capitalization of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71. The business's 50-day moving average price is $0.77 and its two-hundred day moving average price is $1.23. Invivyd, Inc. has a 1 year low of $0.48 and a 1 year high of $3.07.
Invivyd (NASDAQ:IVVD - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The firm had revenue of $14.29 million for the quarter, compared to analyst estimates of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. Sell-side analysts anticipate that Invivyd, Inc. will post -0.52 earnings per share for the current fiscal year.
Institutional Trading of Invivyd
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. raised its holdings in Invivyd by 190.6% during the first quarter. Invesco Ltd. now owns 108,999 shares of the company's stock worth $66,000 after acquiring an additional 71,485 shares in the last quarter. AQR Capital Management LLC grew its stake in Invivyd by 2,051.0% in the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company's stock valued at $249,000 after purchasing an additional 391,617 shares in the last quarter. Marshall Wace LLP bought a new position in Invivyd in the second quarter valued at approximately $158,000. Jane Street Group LLC acquired a new position in shares of Invivyd during the 2nd quarter worth approximately $147,000. Finally, Vanguard Group Inc. increased its position in shares of Invivyd by 46.7% during the 3rd quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company's stock worth $6,339,000 after purchasing an additional 1,834,970 shares during the last quarter. Institutional investors own 70.36% of the company's stock.
Analysts Set New Price Targets
A number of research firms have weighed in on IVVD. BTIG Research reaffirmed a "buy" rating on shares of Invivyd in a research report on Tuesday, July 7th. HC Wainwright reissued a "buy" rating on shares of Invivyd in a research report on Tuesday. Wall Street Zen cut shares of Invivyd from a "hold" rating to a "strong sell" rating in a report on Saturday, May 16th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Invivyd in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $8.00.
Read Our Latest Research Report on IVVD
Key Headlines Impacting Invivyd
Here are the key news stories impacting Invivyd this week:
- Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
- Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
- Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.
About Invivyd
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
